Public BoD papers 26.5.22

Agenda Item 22/22a

Meeting of the Board of Directors Thursday 26 th May 2022 Board Assurance Framework 2022/23

1

Introduction The draft board assurance framework (BAF) 2022/23 was presented to the Board of Directors in March. A complete review of the 2022/23 board assurance framework has taken place by the executive team and company secretary in May 2022 and the framework presented to this meeting shows new risks, amended descriptions of some risks as well as some risks being removed. Updates to risks All risks in the 2022/23 framework have been reviewed to reflect the most up to date situation in the Trust and wider system, as well as the significant global factors impacting the NHS going forward. There is a move away from Covid-19 risks and more focus on a business-as-usual approach to delivery of our objectives. New columns have been added to the BAF. There is now a ‘Risk Appetite’ column. This is categorised in 3 ways with the lowest risk appetite classed as ‘averse’, then ‘cautious’ and ‘eager’ being the highest appetite for the risk. Each risk has a responsible committee against it to indicate where the risk will be discussed, and assurance sought. There are 7 new risks on the BAF 2022/23 as follows; • 1.4 - Inequity of access for patients to Christie services due to delays in expanding care closer to home provision • 5.1 - Lack of on-site capacity for Christie patients resulting in additional pressure on neighbouring organisations • 6.3 - Digital programme unable to support delivery of operational objectives • 7.4 - Failure to deliver organisational development plans to create a sustainable evolving organisational culture that is adaptive to change • 7.6 - Race/Disability discrimination impacting staff experience and therefore patient care • 8.2 - Failure to reach NHS Net Zero Targets (for the emissions we control directly by 2040, and those we can influence, a 80% reductions by 2045) • 8.3 - Reduced ability to provide services and support to patients due to national / global influences (supplies / fuel costs etc) Many of the risks from the 2021/22 BAF remain but have been redescribed to better reflect the current issue, e.g., the healthcare associated infection (HCAI) risk (1.1) now includes Covid-19. Some risks have been removed from the BAF as follows; • Impact of the COVID-19 pandemic on clinical outcomes, safety and experience • Insufficient capacity in the Cancer Hub to manage demand and;

2

95